Upgrade to SI Premium - Free Trial

Rocket Pharmaceuticals (RCKT)

3.86 +0.07 (1.85%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/5/26)

Latest Headlines

Chardan Assumes Rocket Pharmaceuticals (RCKT) at Buy September 1, 2026 7:36 AM - StreetInsider Form 8-K ROCKET PHARMACEUTICALS, For: Aug 21 August 27, 2026 4:06 PM - SEC Filing Form 4 ROCKET PHARMACEUTICALS, For: Aug 18 Filed by: Wilson Martin August 20, 2026 5:30 PM - SEC Filing Form 4 ROCKET PHARMACEUTICALS, For: Aug 18 Filed by: Shah Gaurav August 20, 2026 5:26 PM - SEC Filing Form 144 ROCKET PHARMACEUTICALS, Filed by: Shah Gaurav August 18, 2026 3:50 PM - SEC Filing Form 144 ROCKET PHARMACEUTICALS, Filed by: Wilson Martin August 18, 2026 3:47 PM - SEC Filing Form 144 ROCKET PHARMACEUTICALS, Filed by: Militello John August 18, 2026 3:44 PM - SEC Filing Form 4 ROCKET PHARMACEUTICALS, For: Aug 13 Filed by: Shah Gaurav August 17, 2026 5:52 PM - SEC Filing Form 4 ROCKET PHARMACEUTICALS, For: Aug 13 Filed by: Wilson Martin August 17, 2026 5:50 PM - SEC Filing Form 4 ROCKET PHARMACEUTICALS, For: Aug 11 Filed by: Stevens Christopher James August 13, 2026 4:16 PM - SEC Filing Form 4 ROCKET PHARMACEUTICALS, For: Aug 11 Filed by: Chaudhuri Sarbani August 13, 2026 4:16 PM - SEC Filing Form 144 ROCKET PHARMACEUTICALS, Filed by: Wilson Martin August 13, 2026 4:04 PM - SEC Filing Form 144 ROCKET PHARMACEUTICALS, Filed by: Shah Gaurav August 13, 2026 3:39 PM - SEC Filing Form 144 ROCKET PHARMACEUTICALS, Filed by: Stevens Christopher James August 11, 2026 3:31 PM - SEC Filing Form 144 ROCKET PHARMACEUTICALS, Filed by: Chaudhuri Sarbani August 11, 2026 3:23 PM - SEC Filing Form 8-K ROCKET PHARMACEUTICALS, For: Aug 10 August 10, 2026 4:19 PM - SEC Filing Rocket Pharmaceuticals (RCKT) Tops Q2 EPS by 6c; offers guidance August 10, 2026 4:18 PM - StreetInsider Form 10-Q ROCKET PHARMACEUTICALS, For: Jun 30 August 10, 2026 4:06 PM - SEC Filing Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress August 10, 2026 4:00 PM - BizWire Form 4 ROCKET PHARMACEUTICALS, For: Aug 03 Filed by: Stevens Christopher James August 5, 2026 8:50 PM - SEC Filing Form 4 ROCKET PHARMACEUTICALS, For: Aug 03 Filed by: SOUTHWELL DAVID P August 5, 2026 8:46 PM - SEC Filing TD Cowen: 'Rocket's protocol modifications may be mitigating prior risks' August 3, 2026 9:03 AM - StreetInsider Form 8-K ROCKET PHARMACEUTICALS, For: Aug 03 August 3, 2026 7:42 AM - SEC Filing Rocket Pharmaceuticals reports no safety issues in first 3 RP-A501 patients August 3, 2026 7:00 AM - StreetInsider Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease August 3, 2026 7:00 AM - BizWire Form SCHEDULE 13G ROCKET PHARMACEUTICALS, Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC July 31, 2026 11:41 AM - SEC Filing Form S-8 ROCKET PHARMACEUTICALS, July 14, 2026 4:06 PM - SEC Filing Form 3 ROCKET PHARMACEUTICALS, For: Jul 08 Filed by: Manhede Joseph July 8, 2026 7:05 PM - SEC Filing Form 144 ROCKET PHARMACEUTICALS, Filed by: Malik Fady Ibraham July 7, 2026 3:13 PM - SEC Filing Form 4 ROCKET PHARMACEUTICALS, For: Jun 18 Filed by: WONG RODERICK July 6, 2026 8:00 PM - SEC Filing Form 4 ROCKET PHARMACEUTICALS, For: Jun 18 Filed by: Dolsten Mikael July 6, 2026 8:00 PM - SEC Filing Form 4 ROCKET PHARMACEUTICALS, For: Jun 18 Filed by: Fong Peter July 6, 2026 8:00 PM - SEC Filing Form 4 ROCKET PHARMACEUTICALS, For: Jun 18 Filed by: Malik Fady Ibraham July 6, 2026 8:00 PM - SEC Filing Form 4 ROCKET PHARMACEUTICALS, For: Jun 18 Filed by: SOUTHWELL DAVID P July 6, 2026 8:00 PM - SEC Filing Form 4 ROCKET PHARMACEUTICALS, For: Jun 18 Filed by: BOESS CARSTEN July 6, 2026 8:00 PM - SEC Filing Form 8-K ROCKET PHARMACEUTICALS, For: Jun 24 June 30, 2026 5:16 PM - SEC Filing Form 8-K ROCKET PHARMACEUTICALS, For: Jun 10 June 12, 2026 7:11 AM - SEC Filing Rocket Pharmaceuticals completes $180 million priority review voucher sale June 12, 2026 7:01 AM - StreetInsider Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million June 12, 2026 7:00 AM - BizWire Full Article List